Elsevier

Life Sciences

Volume 39, Issue 8, 25 August 1986, Pages 669-674
Life Sciences

Minireview
Presynaptic dopaminergic modulation of cortical input to the striatum

https://doi.org/10.1016/0024-3205(86)90013-5Get rights and content

First page preview

First page preview
Click to open first page preview

References (46)

  • E.G. McGeer et al.

    Brain Res.

    (1976)
  • R. Schwarcz et al.

    Brain Res.

    (1977)
  • S. Govoni et al.

    Neurosci. Lett.

    (1978)
  • K.P. Minneman et al.

    Brain Res.

    (1978)
  • L. Garau et al.

    Life Sci.

    (1978)
  • T. Hattori et al.

    Brain Res.

    (1982)
  • G.J. Rowlands et al.

    Eur. J. Pharmacol.

    (1980)
  • P.R. Mitchell et al.

    Life Sci.

    (1980)
  • J.C. Stoof et al.

    Eur. J. Pharmacol.

    (1982)
  • I. Creese

    TINS

    (1982)
  • A. Nieoullon et al.

    Life Sci.

    (1982)
  • A. Nieoullon et al.

    Neurosci. Lett.

    (1983)
  • A.D. Sherman et al.

    Neuropharmacol.

    (1984)
  • J. Kornhuber et al.

    Brain Res.

    (1984)
  • A. Nieoullon et al.

    Brain Res.

    (1978)
  • O.V. Godukhin et al.

    Neurosci.

    (1984)
  • J.D. Kocsis et al.

    Brain Res.

    (1977)
  • S. Fujimoto et al.

    Japan. J. Pharmacol.

    (1981)
  • K. Hirata et al.

    Brain Res.

    (1984)
  • J.R. Brown et al.

    Neurosci.

    (1983)
  • S.W. Johnson et al.

    Neuropharmacol.

    (1983)
  • R.M. Beckstead

    Neurosci. Lett.

    (1979)
  • J.J. Bouyer et al.

    Brain Res.

    (1984)
  • Cited by (129)

    • Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies

      2020, Biomaterials
      Citation Excerpt :

      In PD pathogenesis, despite the impaired function of nigrostriatal DAergic neurons and the loss of DA transmitters, an imbalance in GLUT and GABAergic transmitters has also been documented [48,62]. More precisely, in the putamen, GLUT/N-methyl-d-aspartate (NMDA) presynaptically inhibits DA2 on DAergic neurons, thereby substantially increasing DA deficits (Fig. 2) [63,64]. However, NMDA antagonists substantially reverse the dyskinetic effects, while the metabotropic GLUT receptor m5GluR has also been documented to exert a strong inhibitory effect on DAergic neurons in the putamen [65,66].

    • Reappraising striatal D1- and D2-neurons in reward and aversion

      2016, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      Importantly, D2Rs are also found presynaptically, where they can modulate neurotransmitter release (Benoit-Marand et al., 2001). In the striatum, D2Rs are present on corticostriatal inputs and function to decrease glutamate release by presynaptic mechanisms (Kornhuber and Kornhuber, 1986; Maura et al., 1988; Yamamoto and Davy, 1992). Additionally, these Gi/o −coupled inhibitory receptors also play a major part in shaping dopamine transmission (Benoit-Marand et al., 2001).

    • Treatment with 1,2,3,4,-tetrahydroisoquinoline affects glutamate release in the striatum but not the binding of [<sup>3</sup>H]MK-801 to NMDA receptors in the dopaminergic structures of the rat brain

      2009, Pharmacological Reports
      Citation Excerpt :

      Further illustrating the effects of TIQ on the release of neurotransmitters in the mammalian brain, our earlier study demonstrated that a single dose of this compound administered systemically at 100 mg/kg enhanced DA and serotonin (5-HT) release in the rat striatum [28]. Biochemical, behavioral and electrophysiological studies have suggested that DA released from the dopaminergic nigrostriatal terminals exerts inhibitory effects on the activity of the glutamatergic pathways from the cortex and thalamus [14,20,61]. Hence, it was reasonable to assume that TIQ acting indirectly via DA, which activates presynaptic dopamine D2 receptors localized on the terminals of glutamatergic cortico- and thalamostriatal pathways, could decrease glutamate release in the rat striatum.

    • Prenatal protein deprivation in rats induces changes in prepulse inhibition and NMDA receptor binding

      2004, Brain Research
      Citation Excerpt :

      Second, changes in glutamate receptor binding have been observed post-mortem in the brains of patients with schizophrenia. However, the observed changes differ in nature from our results, with increases in receptor binding occurring in cortex [26,45,61,85], decreases in receptor number and gene expression occurring in the hippocampus [31,42,47] and increases in receptor number occurring in striatum [50]. These reported receptor changes are hypothesized to occur as compensatory responses to decreased NMDA-mediated glutamate release [45,85].

    View all citing articles on Scopus
    View full text